Table 2.
Effectiveness of various vaccines on Delta variant
| Name | Category | Country | Company | Effectiveness | Compared to other variants | Reference |
|---|---|---|---|---|---|---|
| BNT162b2 | mRNA | USA | Pfizer | 75%-82% | 2.5-fold↓(compared with B.1.1.7 and P.1) | 50, 67 |
| ChAdOx1(AZD1222) | Viral vector | UK | AstraZeneca | 53%-66% | 4.3-fold↓(compared with B.1.1.7 and P.1) | 67, 68 |
| mRNA-1273 | mRNA | USA | Moderna | 76% | 2.1 to 3.4 fold↓(compared with D614G) | 69, 70 |
| BBV152 /Covaxin | Inactivated | Indian | Bharat Biotech | 65.2% | 7-fold↓(compared with wildtype virus) | 71 |
| Sputnik V | Viral vector | Russia | Gamaleya Institute | 69.85% | 2.5-fold↓(compared with B.1.1.141 and B.1.1.317) | 72 |
| NVX-CoV2373 | Recombinant SARS‐CoV‐2 Spike protein nanoparticle | USA | Novovax | NA | NA | 73 |
| CoronaVac | Inactivated | China | SinoVac | 59% | NA | 74 |
| Ad26.COV2.S | Viral vector | USA | J&J/Janssen | 60% | NA | 75 |